Market Cap (In USD)
26.36 Million
Revenue (In USD)
-
Net Income (In USD)
-10.1 Million
Avg. Volume
414.77 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.512-2.33
- PE
- -
- EPS
- -
- Beta Value
- 1.565
- ISIN
- IL0011809592
- CUSIP
- M74240108
- CIK
- 1875091
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Alon Ben-Noon
- Employee Count
- -
- Website
- https://www.neurosense-tx.com
- Ipo Date
- 2021-12-09
- Details
- NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
More Stocks
-
TTR1technotrans SE
TTR1
-
TTA
-
SAAM
-
PRM
-
RHHBYRoche Holding AG
RHHBY
-
SKUYF
-
AAGAumann AG
AAG
-
ALDLTDelta Plus Group
ALDLT